SCHEMBL2217034

SCHEMBL2217034

O=c1c(CO)c(Nc2cccc(Cl)c2)nc2c(C(F)(F)F)cccn12

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
STK10 O94804 1/20 0.42
SLK Q9H2G2 1/20 0.42
CSNK2A1 P68400 6/20 0.41
CSNK2A2 P19784 5/20 0.41
CSNK2B P67870 5/20 0.41
NPSR1 Q6W5P4 2/20 0.40
KMT2A Q03164 2/20 0.39
FADS1 O60427 1/20 0.39
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.37
CDK1 P06493 3/20 0.37
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
MAPT P10636 1/20 0.36
PRKCQ Q04759 1/20 0.36
SYK P43405 1/20 0.35
IDH1 O75874 1/20 0.35
IDH2 P48735 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15887182 0.89 NPC1 (0.39) NPSR1NPC1CDK1HPGDMAPT
SCHEMBL2217596 0.87 CSNK2A1 (0.43) CSNK2A1CSNK2A2CSNK2BNPSR1KMT2A
SCHEMBL2217975 0.86 CSNK2A1 (0.44) STK10SLKCSNK2A1CSNK2A2CSNK2B
SCHEMBL12462118 0.85 CSNK2A1 (0.43) CSNK2A1CSNK2A2CSNK2BNPSR1KMT2A
SCHEMBL2220828 0.85 NPSR1 (0.55) CSNK2A1CSNK2A2CSNK2BNPSR1KMT2A
SCHEMBL2218507 0.83 TNF (0.44) STK10SLKCSNK2A1CSNK2A2CSNK2B
SCHEMBL2217394 0.79 IGF1R (0.42) CSNK2A1CSNK2A2CSNK2BKMT2AMEN1
SCHEMBL2218427 0.79 MEN1 (0.53) CSNK2A1CSNK2A2CSNK2BNPSR1KMT2A
SCHEMBL15887190 0.78 PTGER3 (0.42) NPSR1NPC1ALDH1A1HPGDMAPT
SCHEMBL2216068 0.78 CSNK2A1 (0.43) CSNK2A1CSNK2A2CSNK2BNPSR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2310388-B1 PYRIDOPYRIMIDINE COMPOUNDS AS ANTI-TUBERCULAR AGENTS PASTEUR INSTITUT KOREA (KR) 2015-08-05 EP claimed
US-8785452-B2 Anti-infective compounds INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2014-07-22 US claimed
EP-2310388-B1 PYRIDOPYRIMIDINE COMPOUNDS AS ANTI-TUBERCULAR AGENTS PASTEUR INSTITUT KOREA (KR) 2015-08-05 EP disclosed
EP-2310388-B1 PYRIDOPYRIMIDINE COMPOUNDS AS ANTI-TUBERCULAR AGENTS PASTEUR INSTITUT KOREA (KR) 2015-08-05 EP disclosed
US-8785452-B2 Anti-infective compounds INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2014-07-22 US disclosed
US-8785452-B2 Anti-infective compounds INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2014-07-22 US disclosed
US-8785452-B2 Anti-infective compounds INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2014-07-22 US disclosed
EP-2730576-A2 Anti-infective compounds Institut Pasteur Korea (KR) 2014-05-14 EP disclosed
EP-2730576-A2 Anti-infective compounds Institut Pasteur Korea (KR) 2014-05-14 EP disclosed
US-20130012506-A1 ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES NO ZAESUNG (KR) 2013-01-10 US disclosed
US-20130012506-A1 ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES NO ZAESUNG (KR) 2013-01-10 US disclosed
US-20130012506-A1 ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES NO ZAESUNG (KR) 2013-01-10 US disclosed
US-20110178077-A1 Anti-infective compounds INSTITUT PASTEUR KOREA (KR) 2011-07-21 US disclosed
US-20110178077-A1 Anti-infective compounds INSTITUT PASTEUR KOREA (KR) 2011-07-21 US disclosed
US-20110178077-A1 Anti-infective compounds INSTITUT PASTEUR KOREA (KR) 2011-07-21 US disclosed
WO-2011085990-A1 ANTI - INFECTIVE PYRIDO (1,2 -A) PYRIMIDINES INSTITUT PASTEUR KOREA (KR) 2011-07-21 WO disclosed
WO-2010003533-A2 ANTI-INFECTIVE COMPOUNDS INSTITUT PASTEUR KOREA (KR) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178077-A1 Anti-infective compounds RABGGTB, ELANE, SERPINB1 STK10 2341/4885SLK 3254/4885CSNK2A1 4707/4885
US-20130012506-A1 ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES TYMS, TYMP, DCTPP1 STK10 3535/4885SLK 3266/4885CSNK2A1 4606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.